Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Apr 2017 | FROM EXTERNAL EXPERTS

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

Nov 2016 | FROM EXTERNAL EXPERTS

An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function

Jan 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

Nov 2015 | FROM EXTERNAL EXPERTS

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Nov 2009 | FROM EXTERNAL EXPERTS

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.